Rebetol Oral Solution

MARCH 01, 2004

Schering-Plough Corp (Kenilworth, NJ) has announced the launch of Rebetol (ribavirin USP) Oral Solution for use in combination with Intron A (interferon alfa- 2b, recombinant) Injection for treating pediatric chronic hepatitis C. The combination of Intron A and Rebetol is indicated for the treatment of patients 3 years of age and older with compensated liver disease previously untreated with alpha interferon. Rebetol Oral Solution represents a new formulation of ribavirin USP, developed specifically to meet the needs of pediatric patients. It comes in bubble-gum flavor. For more information, visit www.scheringplough. com.



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.